The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Shire's 2013 CNS, immunology and metabolic's sales performance.
With the integration of Shire into our UK &Ireland team we will continue to empower our people to be ambitious and change the game for patients, a key achievement of our
He has significant UK experience with GlaxoSmithKline and MSD in most therapeutic areas and, also, in specialist and rare diseases with Takeda Europe and Shire Global.
including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.
A number of treatments on the market are designed to replace factor VII, including both short-acting and newer long-acting versions such as Shire’s Adynovate, Biogen’s Eloctate,
Last year, Takeda acquired Irish biotech company Shire for £46bn, which gave the Japanese pharma company access to a solid platform of rare diseases. ... As well as completing $10bn in divestment transactions, Takeda has made other sacrifices for the
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...